Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.59 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304920 | 1.00 | MDM2 (0.59) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL29397862 | 1.00 | MDM2 (0.59) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL2304915 | 1.00 | MDM2 (0.59) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL29445591 | 1.00 | MDM2 (0.59) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL3724885 | 1.00 | MDM2 (0.59) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL8266129 | 0.91 | PTPN1 (0.60) | MDM2PTPN1 | |
| SCHEMBL8443984 | 0.90 | MDM2 (0.51) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL8933064 | 0.90 | MDM2 (0.52) | MDM2FPR2PTPN1MDM4TP53 | |
| SCHEMBL25264909 | 0.90 | MDM2 (0.62) | MDM2PTPN1MDM4TP53CASP3 | |
| SCHEMBL30510289 | 0.90 | MDM2 (0.62) | MDM2PTPN1MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678652-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-119731195-A | Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS | 中外制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024219480-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-10-24 | — | — | WO | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | MDM2 30/4885FPR2 3678/4885PTPN1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.